Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 16;6(6):CD014463.
doi: 10.1002/14651858.CD014463.pub2.

Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes

Rashmi Verma  1 , Mihir Chandarana  2 , Jessica Barrett  3 , Carmel Anandadas  4 , Sreekumar Sundara Rajan  5
Affiliations

Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes

Rashmi Verma et al. Cochrane Database Syst Rev. .

Abstract

Background: Continual improvement in adjuvant therapies has resulted in a better prognosis for women diagnosed with breast cancer. A surrogate marker used to detect the spread of disease after treatment of breast cancer is local and regional recurrence. The risk of local and regional recurrence after mastectomy increases with the number of axillary lymph nodes affected by cancer. There is a consensus to use radiotherapy as an adjuvant treatment after mastectomy (postmastectomy radiotherapy (PMRT)) in women diagnosed with breast cancer and found to have disease in four or more positive axillary lymph nodes. Despite data showing almost double the risk of local and regional recurrence in women treated with mastectomy and found to have one to three positive lymph nodes, there is a lack of international consensus on the use of PMRT in this group.

Objectives: To assess the effects of PMRT in women diagnosed with early breast cancer and found to have one to three positive axillary lymph nodes.

Search methods: We searched the Cochrane Breast Cancer Group's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov up to 24 September 2021.

Selection criteria: We included randomised controlled trials (RCTs). The inclusion criteria included women diagnosed with breast cancer treated with simple or modified radical mastectomy and axillary surgery (sentinel lymph node biopsy (SLNB) alone or those undergoing axillary lymph node clearance with or without prior SLNB). We included only women receiving PMRT using X-rays (electron and photon radiation), and we defined the radiotherapy dose to reflect what is currently being recommended (i.e. 40 Gray (Gy) to 50 Gy in 15 to 25/28 fractions in 3 to 5 weeks. The included studies did not administer any boost to the tumour bed. In this review, we excluded studies using neoadjuvant chemotherapy as a supportive treatment before surgery.

Data collection and analysis: We used Covidence to screen records. We collected data on tumour characteristics, adjuvant treatments and the outcomes of local and regional recurrence, overall survival, disease-free survival, time to progression, short- and long-term adverse events and quality of life. We reported on time-to-event outcome measures using the hazard ratio (HR) and subdistribution HR. We used Cochrane's risk of bias tool (RoB 1), and we presented overall certainty of the evidence using the GRADE approach.

Main results: The RCTs included in this review were subgroup analyses of original RCTs conducted in the 1980s to assess the effectiveness of PMRT. Hence, the type and duration of adjuvant systemic treatments used in the studies included in this review were suboptimal compared to the current standard of care. The review involved three RCTs with a total of 829 women diagnosed with breast cancer and low-volume axillary disease. Amongst the included studies, only a single study pertained to the modern-day radiotherapy practice. The results from this one study showed a reduction of local and regional recurrence (HR 0.20, 95% confidence interval (CI) 0.13 to 0.33, 1 study, 522 women; low-certainty evidence) and improvement in overall survival with PMRT (HR 0.76, 95% CI 0.60 to 0.97, 1 study, 522 women; moderate-certainty evidence). One of the other studies using radiotherapy techniques that do not reflect modern-day practice reported on disease-free survival in women with low-volume axillary disease (subdistribution HR 0.63, 95% CI 0.41 to 0.96, 1 study, 173 women). None of the included studies reported on PMRT side effects or quality-of-life outcome measures.

Authors' conclusions: Based on one study, the use of PMRT in women diagnosed with breast cancer and low-volume axillary disease indicated a reduction in locoregional recurrence and an improvement in survival. There is a need for more research to be conducted using modern-day radiotherapy equipment and methods to support and supplement the review findings.

PubMed Disclaimer

Conflict of interest statement

RV: none known. currently working as an Oncoplastic Breast Surgeon in the UK National Health Service MC: none known; currently working as a speciality registrar in Breast Surgery in the UK National Health Service JB: none related to this topic. Received grant and salary support from the Medical Research Council UK and honorarium from the Royal Statistical Society of Belgium CA: none known; currently working as a Clinical Oncologist in the UK National Health Service. CA is involved as a Principal Investigator in the SUPREMO Trial, a relevant study on this topic, but, however, does not receive any direct payments for this work. SSR: none known; currently working as an Oncoplastic Breast Surgeon in the UK National Health Service

Figures

1
1
PRISMA flow diagram
2
2
Risk of bias summary for the included studies
1.1
1.1. Analysis
Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 1: Locoregional recurrence (LRR)
1.2
1.2. Analysis
Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 2: Overall survival (OS)
1.3
1.3. Analysis
Comparison 1: PMRT versus no PMRT in women with one to three positive lymph nodes, Outcome 3: Disease‐free survival (DFS)
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD014463

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Killander 2007 {published data only (unpublished sought but not used)}
    1. Killander F, Anderson H, Ryden S, Moller T, Aspegren K, Ceberg J, et al. Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I. European Journal of Cancer 2007;43:2100-8. - PubMed
Killander 2009 {published data only}
    1. Killander F, Anderson H, Ryde S, Moller T, Hafstrom LO, Malmstrom P. Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast 2009;18:309-15. - PubMed
Overgaard 2007 {published data only}
    1. Overgaard M, Nielsena HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiotherapy and Oncology 2007;82:247-53. - PubMed

References to studies excluded from this review

Arriagada 1995 {published data only}
    1. Arriagada R, Rutqvist L E, Mattsson A, Kramar A, Rotstein S. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. Journal of Clinical Oncology 1995;13(12):2869-78. - PubMed
Baum 1980 {published data only}
    1. Baum M, Haybittle JL, Berstock DA. Cancer research campaign (King's/Cambridge) trial for early breast cancer. A detailed update at the 10th year. Lancet 1980;2(8185):55-60. - PubMed
Cahlon 2015 {published data only}
    1. Cahlon O, MacDonald S. Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy - 25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group: Killander F, Anderson H, Kjellen E, et al (Skane Univ Hosp, Lund, Sweden; Lund Univ, Sweden) Eur J Cancer 50:2201-2210, 2014. Breast Diseases 2015;26(1):74-6. - PubMed
Friedl 1983 {published data only}
    1. Friedl W, Scheurlen HR, Henningsen B. The value of radiotherapy after modified radical mastectomy. 10 year results of the Heidelberg Study. Deutsche Medizinische Wochenschrift 1983;108(9):325-30. - PubMed
Gustavsson 1999 {published data only}
    1. Gustavsson A, Bendahl PO, Cwikiel M, Eskilsson J, Thapper KL, Pahlm O. No serious late cardiac effects after adjuvant radiotherapy following mastectomy in premenopausal women with early breast cancer. International Journal of Radiation Oncology, Biology, Physics 1999;43(4):745-54. - PubMed
Houghton 1994 {published data only}
    1. Houghton J, Baum M, Haybittle JL. Role of radiotherapy following total mastectomy in patients with early breast cancer. The Closed Trials Working Party of the CRC Breast Cancer Trials Group. World Journal of Surgery 1994;18(1):117-22. - PubMed
Højris 1999 {published data only}
    1. Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet (London, England) 1999;354(9188):1425-30. - PubMed
Højris 2000 {published data only}
    1. Højris I, Andersen J, Overgaard M, Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. Acta Oncologica 2000;39(3):355-72. - PubMed
Killander 2014 {published data only}
    1. Killander F, Anderson H, Kjellen E, Malmstrom P. Increased cardio and cerebrovascular mortality in breast cancer patients treated with postmastectomy radiotherapy--25 year follow-up of a randomised trial from the South Sweden Breast Cancer Group. European Journal of Cancer 2014;50(13):2201-10. - PubMed
Morgan 2002 {published data only}
    1. Morgan DA, Berridge J, Blamey RW. Postoperative radiotherapy following mastectomy for high-risk breast cancer. A randomised trial. European Journal of Cancer 2002;38(8):1107-10. - PubMed
Nielsen 2006 {published data only}
    1. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. Journal of Clinical Oncology 2006;24(15):2268-75. - PubMed
Osman 2014 {published data only}
    1. Osman MAM, Elkady MS, Nasr KE. For stage II node-positive breast cancer, is it worthwhile to consider adjuvant radiotherapy following mastectomy? Frontiers in Oncology 2014;4:1-8. - PMC - PubMed
Overgaard 2020 {published data only}
    1. Overgaard M, Melgaard Nielsen H, Tramm T, Hojris I, Grantzau T, et al. Postmastectomy RT in high-risk breast cancer. A 30-year update of the DBCG 82bc randomized trial. Radiotherapy and Oncology 2020;152:S171. - PubMed
Ragaz 2005 {published data only}
    1. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute 2005;97(2):116-26. - PubMed
Rutqvist 1990 {published data only}
    1. Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990;66(1):89-96. - PubMed
Rutqvist 1992 {published data only}
    1. Rutqvist LE, Lax I, Fornander T, Johansson H. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. International Journal of Radiation Oncology, Biology, Physics 1992;22(5):887-96. - PubMed
Rutqvist 2006 {published data only}
    1. Rutqvist LE, Johansson H. Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients. Acta Oncologica 2006;45(5):517-27. - PubMed
Schmoor 2000 {published and unpublished data}
    1. Schmoor C, Bastert G, Dunst J, Bojar H, Christmann D, Unbehaun V, et al. Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group. International Journal of Cancer 2000;86(3):408-15. - PubMed
Seegenschmiedt 2000 {published data only}
    1. Seegenschmiedt MH. Long-term cardiac sequelae of adjuvant radiotherapy after mastectomy? Analysis of Danish DBCG-82b/82c trials. Strahlentherapie und Onkologie 2000;176(4):197‐8. - PubMed
Shi 2011 {published data only}
    1. Shi M, Ling R, Xia Y, Luo S, Fu X, Xiao F, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiotherapy and Oncology 2011;100(2):200-4. - PubMed
Smith 2001 {unpublished data only}
    1. Smith L, Mortimer JE. Randomized trial of post-mastectomy radiotherapy in stage II breast cancer in women with one to three positive axillary nodes, phase III. ClinicalTrials.gov 2001.

References to ongoing studies

Velikova 2018 {published and unpublished data}
    1. Velikova G, Williams LJ, Willis S, Dixon JM, Kunkler IH, Russell NS, et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology 2018;19(11):1516-29. - PubMed

Additional references

Bray 2018
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018;68(6):394-424. - PubMed
Burstein 2019
    1. Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals of Oncology 2019;30(10):1541-57. - PubMed
Cardoso 2012
    1. Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. European Journal of Cancer 2012;48(18):3355-77. - PubMed
Chagpar 2003
    1. Chagpar A, Kuerer HM, Hunt KK, Strom EA, Buchholz TA. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. International Journal of Radiation Oncology, Biology, Physics 2003;57(1):128-35. - PubMed
Cochran 1954
    1. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10(1):101-29.
Deeks 2022
    1. Deeks JJ, Higgins JPT, Altman DG, Cochrane Statistical Methods Group. Chapter 10: analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors(s). Cochrane Database of Systematic Reviews. Cochrane, 2022. Available from www.training.cochrane.org/handbook.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. - PubMed
EBCTCG 1995
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. New England Journal of Medicine 1995;333(22):1444-55. - PubMed
EBCTCG 2000
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000;355(9217):1757-70. - PubMed
EBCTCG 2005
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366(9503):2087-106. - PubMed
EBCTCG 2014
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383(9935):2127-35. - PMC - PubMed
Fine 1999
    1. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999;94:496-509.
Fisher 1998
    1. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. Journal of Clinical Oncology 1998;16(2):441-52. - PubMed
Fisher 2002
    1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine 2002;347(16):1233-41. - PubMed
Garg 2007
    1. Garg AK, Oh JL, Oswald MJ, Huang E, Storm EA, Perkins GH, et al. Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. International Journal of Radiation Oncology, Biology, Physics 2007;69(5):1478-83. - PMC - PubMed
Goldhirsch 2009
    1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Annals of Oncology 2009;20(8):1319-29. - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 3 March 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.
Haviland 2016
    1. Havilnad JS, Bentzen SM, Bliss JM, Yarnold JR. Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: an analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. Radiotherapy and Oncology 2016;121:420-3. [PMID: ] - PubMed
Headon 2016
    1. Headon H, Kasem A, Almukbel R, Mokbel K. Improvement of survival with postmastectomy radiotherapy in patients with 1-3 positive axillary nodes: a systematic review and meta analysis of the current literature. Molecular and Clinical Oncology 2016;5:429-36. - PMC - PubMed
Hennequin 2013
    1. Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. International Journal of Radiation Oncology, Biology, Physics 2013;86(5):860-6. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
Katz 2000
    1. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. Journal of Clinical Oncology 2016;18(15):2817-27. - PubMed
Li 2013
    1. Li Y, Moran MS, Huo Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with T1-T2 and 1-3 positive lymph nodes: a meta-analysis. PLoS ONE 2013;8(12):e81765. - PMC - PubMed
McCaw 2022
    1. McCaw ZR, Claggett BL, Tian L, Solomon SD, Berwanger O, Pfeffer MA, et al. Practical recommendations on quantifying and interpreting treatment effects in the presence of terminal competing risks: a review. JAMA Cardiology 2022;7(4):450-6. - PubMed
Mukesh 2014
    1. Mukesh MB, Duke S, Parashar D, Wishart G, Coles CE, Wilson C. The Cambridge post-mastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection. Radiotherapy and Oncology 2014;110(3):461-6. - PubMed
NICE 2018
    1. National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and management. NICE Clinical Guidelines, NG101 2018. - PubMed
Nielsen 2006
    1. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. Journal of Clinical Oncology 2016;24(15):2268-75. - PubMed
Osman 2014
    1. Osman MAM, Elkady MS, Nasr KE. For stage II node positive breast cancer, is it worthwhile to consider adjuvant radiotherapy following mastectomy? Frontiers in Oncology 2014;4:1-8. [DOI: 10.3389/fonc.2014.00326] - DOI - PMC - PubMed
Overgaard 1997
    1. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New England Journal of Medicine 1997;337(14):949-55. - PubMed
Overgaard 1999
    1. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 199;353(9165):1641-8. [DOI: 10.1016/S0140-6736(98)09201-0.] - DOI - PubMed
Overgaard 2007
    1. Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiotherapy and Oncology 2007;82(3):247-53. - PubMed
Page 2021
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffman TC, Mulrow CD et al. The PRISMA 2020 sttatement: an updated guideline for reporting systematic reviews.. BMJ 2021;372:n71. - PMC - PubMed
Page 2022
    1. Page MJ, Higgins JPT, Sterne JAC. Chapter 13: assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Parmar 1998
    1. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. - PubMed
Poortmans 2015
    1. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. New England Journal of Medicine 2015;373(4):317-27. - PubMed
Ragaz 2005
    1. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute 2005;97(2):116-26. - PubMed
Recht 2016
    1. Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. Journal of Clinical Oncology 2016;34(36):4431-42. - PubMed
RevMan Web [Computer program]
    1. Review Manager Web (RevMan Web). Version 1.22. The Cochrane Collaboration, 2020. Available from revman.cochrane.org.
Salerno 2017
    1. Salerno KE. NCCN guidelines update: evolving radiation therapy recommendations for breast cancer. Journal of the National Comprehensive Cancer Network 2017;15(s5):682-4. - PubMed
Schünemann 2022
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
SEER 2020
    1. Surveillance, Epidemiology, and End Results Program - National Cancer Institute, 2020. Female Breast Cancer - Cancer stat facts. Available from seer.cancer.gov/statfacts/html/breast.html (accessed July 2021).
Shi 2011
    1. Shi M, Ling R, Xia Y, Luo S, Fu X, Xiao F, et al. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiotherapy and Oncology 2011;100(2):200-4. - PubMed
Siegel 2020
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians 2020;70(1):7-30. - PubMed
START TRIAL A
    1. The START Trialist Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology 2008;9(4):331-41. - PMC - PubMed
START TRIAL B
    1. The START Trialist Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371(9618):1098-107. - PMC - PubMed
Thorsen 2016
    1. Thorsen LB, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. Journal of Clinical Oncology 2016;34(4):314-20. - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. - PMC - PubMed
Truong 2005
    1. Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2005;61(5):1337-47. - PubMed
Van Tienhoven 1999
    1. Van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG- 82TM). European Journal of Cancer 1999;35(1):32-8. - PubMed
Wallgren 2003
    1. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. Journal of Clinical Oncology 2003;21(7):1205-13. - PubMed
Whelan 2000
    1. Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta- analysis. Journal of Clinical Oncology March 2000;18(6):1220-9. - PubMed
Whelan 2015
    1. Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al for the MA20 Study Investigators. Regional nodal irradiation in early-stage breast cancer. New England Journal of Medicine 2015;373(4):307-16. - PMC - PubMed

Publication types